MUNICH, June 28, 2010 /PRNewswire/ —
– 3D Images Provide New Approach to Monitoring Bone Changes
Interim data from a prospective Investigator Initiated Trial
(IIT) presented today at the ECTS, the 37th European Symposium on
Calcified Tissues, in Glasgow,
demonstrates that EVISTA(R) (raloxifene 60mg; once-daily,
distributed in 34 countries by DAIICHI SANKYO), indicated for the
treatment and prevention of osteoporosis in postmenopausal women,
improves bone quality as measured by the high-resolution peripheral
quantitative computed tomography (HRpQCT). Dr. Radspieler,
Investigator of the IIT at the Osteoporosis Diagnostic- und Therapy
centre Munich, evaluated
prospectively micro-architectural changes of the bone of patients
being treated with EVISTA(R) for 15.1 months. The trial showed
that, all parameters analysed improved over the treatment period.
Exemplary, raloxifene increased volumetric trabecular by 2.9% and
3.9% and cortical bone densities by 1.1% and 0.7% in the radius and
the tibia respectively.
Dr. Helmut Radspieler comments:
“With the help of 3D images we can now actually see into the
micro-structure of bones. This makes it possible to determine the
efficacy of different treatments, as shown here with raloxifene.”
He continues; “We now understand better and are also able to
visualise that bone structure and not bone density alone is crucial
to retain bone quality”.
Bone mineral density (BMD) assessed by dual-energy X-ray
absorptiometry (DXA) is the current gold standard for the diagnosis
of osteoporosis, however, it is not as effective in the measurement
of the therapeutic effect of an osteoporosis treatment(1). By using
a new thre
‘/>”/>
